MétaCan
Menu
Back to cohort
Record W4372335396 · doi:10.1002/mds.29410

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

2023· review· en· W4372335396 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueMovement Disorders · 2023
Typereview
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsToronto Western HospitalKrembil FoundationUniversity of TorontoUniversity Health Network
FundersDaiichi Sankyo EuropeNovartis PharmaNational Institutes of HealthIpsenOno PharmaceuticalJapan Society for the Promotion of ScienceUCB PharmaUniversität zu KölnCHDI FoundationDeutsche Gesellschaft für NeurologieJapan Agency for Medical Research and DevelopmentGovernment of the United KingdomOtsuka PharmaceuticalEisaiAcorda TherapeuticsUniversity of CambridgeSeqirusChulalongkorn UniversityParkinson's UKRIKENThailand Research FundNational Medical Research CouncilBoehringer Ingelheim JapanThiemann StiftungMichael J. Fox Foundation for Parkinson's ResearchParkinson's FoundationNational Science and Technology Development AgencyUniversity of PennsylvaniaU.S. Department of Veterans AffairsAlexion PharmaceuticalsNihon Medi-PhysicsEU Joint Programme – Neurodegenerative Disease ResearchWellcome TrustH. Lundbeck A/SSunovionCrown Property BureauDeutsche ForschungsgemeinschaftBoston Scientific CorporationBiogenAllerganJapan Science and Technology AgencyInternational Parkinson and Movement Disorder SocietyACADIA PharmaceuticalsRoyal SocietyTeva Pharmaceutical IndustriesBristol-Myers SquibbNational Institute for Health and Care ResearchMedical Research CouncilBritannia PharmaceuticalsKisseiNewton Fund
KeywordsLevodopaSystematic reviewMedicineClinical trialMEDLINEPharmacotherapyDiseaseParkinson's diseaseIntensive care medicineMedical physicsPsychiatryInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed. OBJECTIVES: To update LED conversion formulae based on a systematic review. METHODS: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency. RESULTS: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon. CONCLUSIONS: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.307
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.335
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it